Enanta Pharmaceuticals Inc.

ENTA | NASDAQ

Price Alert Chart Builder DCF Calculator

$12.11

-$0.09 (-0.74%)

At close: Sep 21, 2026, 4:00 PM ET

$12.11

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.74%

(1D)

Rating

Updated: Sep 4, 2026

28.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $352.14M

1D Range

11.94 12.27

52W Range

7.05 17.15

Valuation (TTM)

PE -4.75

PB 3.48

EV/EBITDA -4.70

Valuation (NTM)

Forward PE N/A

Forward PEG 0.57

Price Target $20

Cash Flow

FCF Yield -10.5%

SBC Adj. FCF Yield -14.8%

SBC Impact -41.3%

Margins

Gross Margin 98.2%

Operating Margin -90.0%

FCF Margin -56.6%

Growth (CAGR)

Revenue 3Y | 5Y -6.8% | -7.7%

Dil EPS 3Y | 5Y 35.3% | 17.6%

FCF 3Y | 5Y 52.6% | 22.6%

Returns

ROA -21.3%

ROE -61.8%

ROIC -23.8%

Financial Health

Net Cash

$133.85M

Current Ratio 3.76

Interest Coverage -4.55

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its re...

Sector Healthcare

Industry Biotechnology

Employees 120

IPO Date Mar 20, 2013

Website www.enanta.com

Fiscal Year October - September

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 16, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$20

Upside

+65.15%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞